Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.
Kim Duff, Arianna Soresini, Nancy Wolf and 6 others
PMID 40072841WHAT IT FOUND
Nurses are central to transitioning CIDP patients from IVIG to home-based subcutaneous infusion.
Practical guidance covers needle selection, pump settings, and managing local reactions. The ADVANCE-CIDP 1 trial data cited shows reduced relapse rates and high patient satisfaction with this approach.
Key findings
01The ADVANCE-CIDP 1 trial reported that hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG 10%) significantly reduced relapse rates compared to placebo.
02Nurses play a critical role in patient training, managing the transition from clinic to home infusion, and addressing practical challenges like dexterity issues or pump alarms.
03Local adverse events such as swelling and erythema are common but typically mild and resolve within 24 to 48 hours; management strategies include adjusting needle length, infusion rate, or site placement.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a narrative review, not a systematic review, so the selection of evidence may be biased. The ADVANCE-CIDP 1 trial had a short duration (6 months) and included patients already stabilized on IVIG, so results may not generalize to newly diagnosed or unstable patients. Home infusion was not permitted in some regions due to regulations, limiting the applicability of home-care guidance in those settings. The review includes manufacturer-sponsored guidance, and some practical tips are based on study experience rather than controlled trials.
Declared interests
The article discusses fSCIG 10% (HyQvia), manufactured by Baxalta/Takeda. The ADVANCE-CIDP 1 trial was sponsored by Baxalta US Inc. The 'Train the Trainer' program was offered by IQVIA, a contract research organization. Authors may have financial ties to the manufacturer or research sponsors.
The easy way to misread this
Do not assume fSCIG 10% is superior to IVIG for all patients; the trial compared it to placebo in patients already stabilized on IVIG. Also, local injection site reactions are very common and require active nursing management, not just patient education.